KRAS and lung adenocarcinoma: Multiple activating mutations in oncogenes have been found in lung adenocarcinomas, including in the following genes: EGFR (39%), KRAS (20%), ALK fusions (notably with EML4) (4%), ERBB2 (3%) and BRAF (3%), which are found to be mutually exclusive [6]–[8].